Acrigen
2 known investors
Acrigen develops precision gene editing systems based on CRISPR, using novel αCas and μCas nuclease libraries paired with engineered anti-CRISPR (ErAcr) proteins to reduce off-target edits. The technology is aimed at human therapeutics for genetic diseases and is offered for licensing.